Lysoway Therapeutics

📍 Cambridge, United States🗓 Founded 2020👥 6 employees💰 Last funded Apr 2026
Biotechnology Research🌐 lysoway.com
Website LinkedIn
Lysoway Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines targeting lysosomal ion channels to restore the age-related decline of autophagy-lysosomal pathway (ALP) function. Leveraging proprietary discovery capabilities, including structure-based drug design, Lysoway has developed potent, selective, and highly brain-penetrant modulators of key lysosomal ion channels, including TRPML1 and TMEM175. By harnessing the cell’s natural cellular clearance machinery, Lysoway aims to address upstream disease mechanisms in age-related neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
China
1
United States
1
Frequently asked questions
Who invested in Lysoway Therapeutics?
Lysoway Therapeutics has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Lysoway Therapeutics last raise funding?
The most recent investment in Lysoway Therapeutics recorded on gritt.io was in April 2026.
When was Lysoway Therapeutics founded?
Lysoway Therapeutics was founded in 2020.
What industry is Lysoway Therapeutics in?
Lysoway Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Lysoway Therapeutics based?
Lysoway Therapeutics is headquartered in Cambridge, United States.